Bambec provides effective bronchodilation in patients with nocturnal asthma both during the night and up to 24 hours after drug intake.
| 1. Petrie GR, et al. Respir Med 1993; 87: 581–5 |
| |
Compared with placebo, Bambec significantly increased PEF rates and significantly reduced the use of inhaled beta2-agonists, number of nocturnal awakenings, and nocturnal asthma symptom scores. More patients reported a significantly improved quality of sleep and overall state of health after Bambec treatment, than after placebo.
Bambec 20 mg (given in the evening) improves asthma symptom control compared with placebo
Mean (± SD) asthma symptom scores, number of nocturnal awakenings, use of inhaled beta2-agonists, and lung function results in 26 patients with nocturnal asthma treated with placebo or Bambec 20 mg once each evening for 14 days (mean values of last 10 days).
Adapted from Petrie et al., 1993. |
| |
| 2. Persson G, et al. Eur Respir J 1995; 8: 34–9 |
| |
Bambec produced marked increases in PEF rate values over a 24-hour period. The maximum bronchodilatory effect was observed at 4 a.m., suggesting that Bambec is very suitable for patients with nocturnal asthma.
Evening administration of Bambec
Changes in PEF versus time during the last 24 hours at the end of the reference period and the first week of treatment. The onset of effect was more rapid and the peak effect more sustained with Bambec 20 mg than Bambec 10 mg.
Adapted from Persson et al., 1995. |
| |
| 3. D’Alonzo GE, et al. Chest 1995; 107: 406–12 |
| |
In a comparison of morning and evening administration of Bambec 20 mg daily, evening dosing led to higher nocturnal plasma terbutaline levels with improved airways patency on awakening. The maximum increase in FEV1 compared with placebo occurred at 4 a.m., suggesting good nocturnal asthma control.
Evening administration of Bambec results in improved morning FEV1
Mean (±SEM) FEV1 in 22 asthmatic patients who completed 1 weeks’ treatment with placebo or Bambec 20 mg once daily, administered in the morning or evening.
Adapted from D’Alonzo et al., 1995. |
| |
| 4. Wempe JB, et al. J Allergy Clin Immunol 1992; 90: 349–57 |
| |
| Bambec 20 mg at night reduced nocturnal asthma symptoms and circadian variation in FEV1. Bambec improved responsiveness to histamine more at night than during the day, thus decreasing circadian variation: at 4 am, the increase in PC20 was 0.8 doubling concentrations, compared with placebo. |
| |
| 5. Persson G, et al. Curr Ther Res 1995; 56: 457–65 |
| |
Bambec 20 mg once daily and terbutaline 5 mg three-times daily produced similar improvements in lung function. However, Bambec caused better overall improvement in asthma symptom scores during the day and at night.
Bambec administration in the evening provides greater control of asthma symptoms than terbutaline
Mean (±SD) asthma symptom scores reported at night and during the day in patients with chronic asthma treated for 7 days. Bambec was administered in the evening.
Adapted from Persson et al., 1995. |
| |
back to top 
|
|
